KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBIT Margin (2019 - 2025)

Aurinia Pharmaceuticals' EBIT Margin history spans 7 years, with the latest figure at 43.1% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 4589.0% year-over-year to 43.1%; the TTM value through Dec 2025 reached 37.06%, up 3906.0%, while the annual FY2025 figure was 37.06%, 3906.0% up from the prior year.
  • EBIT Margin reached 43.1% in Q4 2025 per AUPH's latest filing, up from 40.49% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 43.1% in Q4 2025 to a low of 5529.87% in Q1 2021.
  • Average EBIT Margin over 5 years is 361.57%, with a median of 34.4% recorded in 2023.
  • Peak YoY movement for EBIT Margin: soared 14557048bps in 2021, then plummeted -1280bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 139.74% in 2021, then increased by 29bps to 98.82% in 2022, then skyrocketed by 33bps to 65.8% in 2023, then skyrocketed by 96bps to 2.79% in 2024, then surged by 1646bps to 43.1% in 2025.
  • Per Business Quant, the three most recent readings for AUPH's EBIT Margin are 43.1% (Q4 2025), 40.49% (Q3 2025), and 28.69% (Q2 2025).